{"id":14982,"date":"2026-03-26T09:00:00","date_gmt":"2026-03-26T08:00:00","guid":{"rendered":"https:\/\/www.digital-chiefs.de\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/"},"modified":"2026-06-10T09:47:14","modified_gmt":"2026-06-10T07:47:14","slug":"medtech-ma-why-mdr-compliance-has-become-a-deal-breaker","status":"publish","type":"post","link":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/","title":{"rendered":"MedTech M&#038;A: Why MDR Compliance Has Become a Deal-Breaker"},"content":{"rendered":"\n<p style=\"display:inline-block;background:#d65663;color:#fff;padding:4px 14px;border-radius:20px;font-size:0.85em;margin-bottom:18px;\">5 min read<\/p>\n\n<p><strong>When acquiring a MedTech company, buyers scrutinize revenue, EBITDA, and customer contracts. But who checks the MDR certification status? In the MedTech industry, regulatory due diligence increasingly determines whether a deal happens &#8211; or fails entirely. Seventy percent of companies have withdrawn products from the market; 91% cite certification costs as the primary reason. For investors, compliance posture has become the new risk profile.<\/strong><\/p>\n\n\n<h2>TL;DR<\/h2>\n<div style=\"background:#fafafa;border-left:4px solid #d65663;padding:20px 24px;margin:16px 0 32px 0;border-radius:4px;\">\n<ul>\n<li><strong>70% have withdrawn products:<\/strong> The MDR has forced seven out of ten MedTech companies to pull products from the European market. Of these withdrawn products, 58% continue to be sold outside the EU (BVMed\/DIHK survey).<\/li>\n<li><strong>Certification costs: up 124%:<\/strong> Fees charged by Notified Bodies have more than doubled. Per individual certification: up to \u20ac500,000 (DIHK\/MedicalMountains\/SPECTARIS, 2023).<\/li>\n<li><strong>Only 51 Notified Bodies in the EU:<\/strong> Under the previous directives, there were 80. Capacity constraints now cause wait times of 12 to 18 months.<\/li>\n<li><strong>20% lack alternatives:<\/strong> Nearly one in five withdrawn products has no equivalent alternative on the market &#8211; especially true for specialty implants, niche diagnostics, and pediatric devices.<\/li>\n<li><strong>Compliance is the new due diligence priority:<\/strong> Private equity investors and strategic buyers now assess MDR status as a deal-breaker. A portfolio with expiring certificates represents a discount &#8211; not a premium.<\/li>\n<\/ul>\n<\/div>\n\n\n<h2 style=\"margin-top:32px;margin-bottom:16px;\">Why MDR Compliance Has Become a Valuation Criterion<\/h2>\n\n<p>In traditional MedTech M&#038;A due diligence, finances, intellectual property, and customer relationships take center stage. Regulatory status was a simple checkbox: CE marking present, quality management system certified &#8211; done. The MDR has shattered that logic.<\/p>\n\n<p>A CE marking under the former Medical Device Directive had no expiry date. Under the MDR, CE markings are valid for only five years and require full re-certification by a Notified Body. For a MedTech portfolio comprising 50 products, this means: 50 re-certifications, each costing up to \u20ac500,000, waiting over a year for slots &#8211; and the risk that the Notified Body issues conditions requiring product modifications.<\/p>\n\n<div class=\"evm-stat evm-stat-highlight\" style=\"text-align:center;background:#0a1e3d;border-radius:12px;padding:32px 24px;margin:32px 0;\">\n<div style=\"font-size:48px;font-weight:700;color:#fff;letter-spacing:-0.03em;\">124 %<\/div>\n<div style=\"font-size:15px;color:rgba(255,255,255,0.9);margin-top:8px;max-width:400px;margin-left:auto;margin-right:auto;\">Increase in fees charged by Notified Bodies since MDR implementation<\/div>\n<div style=\"font-size:12px;color:rgba(255,255,255,0.5);margin-top:8px;\">Source: DIHK\/MedicalMountains\/SPECTARIS, 2023<\/div>\n<\/div>\n\n<p>For a private equity investor evaluating a MedTech SME, this fundamentally alters valuation. Questions are no longer \u201cWhat\u2019s the revenue?\u201d but rather: <em>How many certificates expire within the next 24 months? Is there a confirmed slot with a Notified Body? What will it cost to re-certify the entire portfolio? And which products are not worth re-certifying &#8211; and must therefore be written off?<\/em><\/p>\n\n<h2 style=\"margin-top:32px;margin-bottom:16px;\">Hidden Risks Within the Portfolio<\/h2>\n\n<p>The BVMed survey reveals: 70% of member companies have withdrawn products. Fifty-five percent report that suppliers have ceased operations. In 38% of cases, supplier failures triggered their own product withdrawals. These cascading effects go unexamined in standard due diligence.<\/p>\n\n<p>Even more critical: 58% of products withdrawn from the EU market continue to be sold outside the EU &#8211; primarily in the U.S. This may sound like a safety net, yet it carries strategic risk: A company selling its most profitable products exclusively in the U.S. becomes dependent on a single market. If the FDA tightens regulation &#8211; which is plausible given mounting pressure from Congress &#8211; the second leg of its business vanishes.<\/p>\n\n<blockquote style=\"border-left:4px solid #d65663;margin:32px 0;padding:20px 24px;background:#0a1e3d;border-radius:0 8px 8px 0;font-size:1.1em;line-height:1.6;color:rgba(255,255,255,0.9);\">\n\u201cThe SME-dominated sector is suffocating under bureaucratic burdens and reporting obligations &#8211; without any tangible improvement in patient care or safety.\u201d\n<cite style=\"display:block;margin-top:12px;font-size:0.8em;color:rgba(255,255,255,0.5);font-style:normal;\">&#8211; Dr. Marc-Pierre M\u00f6ll, Managing Director, BVMed (BVMed Autumn Survey, October 2025)<\/cite>\n<\/blockquote>\n\n<h2 style=\"margin-top:32px;margin-bottom:16px;\">Five Questions for Regulatory Due Diligence<\/h2>\n\n<p>Every board reviewing a MedTech acquisition or investment should ask &#8211; and demand substantiated answers to &#8211; these five questions:<\/p>\n\n<p><strong>1. Certificate expiry timelines:<\/strong> When do MDR certificates for each product in the portfolio expire? Is there a pipeline plan for re-certifications? What is the cumulative investment volume required?<\/p>\n\n<p><strong>2. Relationship with Notified Bodies:<\/strong> Does the company hold a binding contract with a Notified Body &#8211; or is it merely on a waiting list? A company without a secured slot is a company with insecure market access.<\/p>\n\n<p><strong>3. NIS2 readiness:<\/strong> Is the company registered with the BSI (Federal Office for Information Security)? Does it maintain documented IT risk management? Since December 2025, NIS2 applies without transitional periods. Non-compliance is already a violation.<\/p>\n\n<p><strong>4. PFAS exposure:<\/strong> Which products contain PFAS chemicals? Are substitution plans in place? An ECHA decision is expected in 2026. A portfolio heavily reliant on PFAS &#8211; with no migration strategy &#8211; is a silent devaluation factor.<\/p>\n\n<p><strong>5. R&#038;D pipeline:<\/strong> 53% of MedTech companies have scaled back R&#038;D projects; 46% cut them by more than 75%. An empty pipeline means you\u2019re not buying growth &#8211; you\u2019re buying a declining asset base.<\/p>\n\n<h2 style=\"margin-top:32px;margin-bottom:16px;\">The Counterargument: Is Now the Right Time to Buy?<\/h2>\n\n<p>One can also interpret MDR pressure as a buying opportunity. Companies selling under regulatory strain are cheaper than they were three years ago. Buyers capable of clearing compliance hurdles &#8211; by leveraging the infrastructure of a larger organization &#8211; can acquire niche products at attractive valuations and retain them in the EU while competitors abandon them.<\/p>\n\n<p>For strategic buyers with existing MDR infrastructure (established relationships with Notified Bodies, an in-house Regulatory Affairs team, and a QMS compliant with ISO 13485), this consolidation phase may be precisely the right moment. The art lies in distinguishing between companies whose products lose value under regulatory pressure &#8211; and those whose products gain value, simply because competitors exit the market.<\/p>\n\n<p>In the global medtech market &#8211; growing at double-digit rates &#8211; companies holding both fully certified EU portfolios <em>and<\/em> FDA clearance are the most attractive acquisition targets. Dual certification is becoming a premium differentiator. Those who recognize this are buying smart &#8211; and cheaply.<\/p>\n\n<h2 style=\"margin-top:32px;margin-bottom:16px;\">Frequently Asked Questions<\/h2>\n\n<details style=\"border-bottom:1px solid #e0e0e0;padding:10px 0;\">\n<summary style=\"cursor:pointer;font-size:15px;\"><strong>How much does an MDR re-certification cost?<\/strong><\/summary>\n<p style=\"margin:8px 0 4px 8px;\">Up to \u20ac500,000 per individual product. Average fees charged by Notified Bodies have risen by 124%. For a mid-sized MedTech portfolio, cumulative re-certification costs can range from \u20ac1 million to \u20ac5 million.<\/p>\n<\/details>\n\n<details style=\"border-bottom:1px solid #e0e0e0;padding:10px 0;\">\n<summary style=\"cursor:pointer;font-size:15px;\"><strong>How many Notified Bodies are authorized for MDR certification?<\/strong><\/summary>\n<p style=\"margin:8px 0 4px 8px;\">Currently 51 (as of December 2025). Under the prior directives, there were 80. Wait times for certification slots range from 12 to 18 months. Seventy-five percent of certification procedures take over 12 months.<\/p>\n<\/details>\n\n<details style=\"border-bottom:1px solid #e0e0e0;padding:10px 0;\">\n<summary style=\"cursor:pointer;font-size:15px;\"><strong>Why are MedTech products being withdrawn from the EU market?<\/strong><\/summary>\n<p style=\"margin:8px 0 4px 8px;\">Ninety-one percent of companies cite certification costs as the main reason. For niche products with low unit volumes, re-certification effort exceeds projected EU revenue. Fifty-eight percent of these withdrawn products continue to be sold outside the EU &#8211; mainly in the U.S.<\/p>\n<\/details>\n\n<details style=\"border-bottom:1px solid #e0e0e0;padding:10px 0;\">\n<summary style=\"cursor:pointer;font-size:15px;\"><strong>What should PE investors focus on during MedTech acquisitions?<\/strong><\/summary>\n<p style=\"margin:8px 0 4px 8px;\">Five key points: expiry timelines for all product certificates; contractual relationship with a Notified Body (not just a waitlist position); NIS2 compliance (mandatory since December 2025); PFAS exposure across the portfolio; and the state of the R&#038;D pipeline (53% of companies have reduced projects).<\/p>\n<\/details>\n\n<div style=\"background:#0a1e3d;border-radius:8px;padding:20px 24px;margin:24px 0;border-top:3px solid #d65663;\">\n<h2 style=\"margin-top:0;margin-bottom:12px;font-size:1.05em;color:#fff;\">Editor\u2019s Reading Recommendations<\/h2>\n<ul>\n<li><a href=\"https:\/\/mybusinessfuture.com\/medtech-mittelstand-mdr-nis2-pfas-regulierung-2026\/\" style=\"color:#d65663;\">MedTech SMEs in 2026: Simultaneous pressures from MDR, NIS2, PFAS, and U.S. tariffs (MBF)<\/a><\/li>\n<li><a href=\"https:\/\/mybusinessfuture.com\/ki-medizinprodukte-fda-zulassungen-europa-ai-act-2026\/\" style=\"color:#d65663;\">1,451 AI-based medical devices cleared in the U.S. (MBF)<\/a><\/li>\n<\/ul>\n<\/div>\n\n<p style=\"text-align:right;font-style:italic;color:rgba(255,255,255,0.5);font-size:0.85em;\">Header Image Source: Pexels \/ Mikhail Nilov (px:7579831)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>5 min read When acquiring a MedTech company, buyers scrutinize revenue, EBITDA, and customer contracts. But who checks the MDR certification status? In the MedTech industry, regulatory due diligence increasingly determines whether a deal happens &#8211; or fails entirely. Seventy percent of companies have withdrawn products from the market; 91% cite certification costs as the [&hellip;]<\/p>\n","protected":false},"author":114,"featured_media":15529,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_focuskw":"mdr compliance","_yoast_wpseo_title":"MDR Compliance: Essential Guide for MedTech M&A Deals","_yoast_wpseo_metadesc":"MDR Compliance: Future-proof your MedTech acquisitions. Learn due diligence secrets & boost deal value today!","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":0,"_yoast_wpseo_twitter-image":"","_yoast_wpseo_twitter-image-id":0,"featured_post_sortierung":0,"featured_post":0,"pre_headline":"","bildquelle":"","teasertext":"","language":"de","_evm_slot_owner":"","_evm_translation_lang":"","_wp_old_slug":[],"footnotes":""},"categories":[674],"tags":[],"class_list":["post-14982","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-smart-city-smart-industry","entry"],"wpml_language":"en","wpml_translation_of":14402,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MDR Compliance: Essential Guide for MedTech M&amp;A Deals<\/title>\n<meta name=\"description\" content=\"MDR Compliance: Future-proof your MedTech acquisitions. Learn due diligence secrets &amp; boost deal value today!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MDR Compliance: Essential Guide for MedTech M&amp;A Deals\" \/>\n<meta property=\"og:description\" content=\"MDR Compliance: Future-proof your MedTech acquisitions. Learn due diligence secrets &amp; boost deal value today!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/\" \/>\n<meta property=\"og:site_name\" content=\"Digital Chiefs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/digitalchiefs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-26T08:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T07:47:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1880\" \/>\n\t<meta property=\"og:image:height\" content=\"1253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tobias Massow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@digital_chiefs\" \/>\n<meta name=\"twitter:site\" content=\"@digital_chiefs\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tobias Massow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/\"},\"author\":{\"name\":\"Tobias Massow\",\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/#\/schema\/person\/7a9e40318a8c36352e7a694f6df4d5c8\"},\"headline\":\"MedTech M&#038;A: Why MDR Compliance Has Become a Deal-Breaker\",\"datePublished\":\"2026-03-26T08:00:00+00:00\",\"dateModified\":\"2026-06-10T07:47:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/\"},\"wordCount\":1120,\"publisher\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg\",\"articleSection\":[\"Smart City & Smart Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/\",\"url\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/\",\"name\":\"MDR Compliance: Essential Guide for MedTech M&A Deals\",\"isPartOf\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg\",\"datePublished\":\"2026-03-26T08:00:00+00:00\",\"dateModified\":\"2026-06-10T07:47:14+00:00\",\"description\":\"MDR Compliance: Future-proof your MedTech acquisitions. Learn due diligence secrets & boost deal value today!\",\"breadcrumb\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#primaryimage\",\"url\":\"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg\",\"contentUrl\":\"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg\",\"width\":1880,\"height\":1253},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.digital-chiefs.de\/en\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MedTech M&#038;A: Why MDR Compliance Has Become a Deal-Breaker\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/#website\",\"url\":\"https:\/\/www.digital-chiefs.de\/en\/\",\"name\":\"Digital Chiefs\",\"description\":\"Architekten des digitalen Deutschlands\",\"publisher\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.digital-chiefs.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/#organization\",\"name\":\"Digital Chiefs\",\"url\":\"https:\/\/www.digital-chiefs.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2020\/05\/cropped-digital-chiefs-logo-klein.jpg\",\"contentUrl\":\"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2020\/05\/cropped-digital-chiefs-logo-klein.jpg\",\"width\":190,\"height\":190,\"caption\":\"Digital Chiefs\"},\"image\":{\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/digitalchiefs\/\",\"https:\/\/x.com\/digital_chiefs\",\"https:\/\/www.linkedin.com\/company\/digital-chiefs\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.digital-chiefs.de\/en\/#\/schema\/person\/7a9e40318a8c36352e7a694f6df4d5c8\",\"name\":\"Tobias Massow\",\"description\":\"Tobias Massow ist Gesch\u00e4ftsf\u00fchrer der Evernine Media GmbH und Herausgeber von Digital Chiefs. Er verantwortet die strategische Ausrichtung des Magazins und des MBF Media Netzwerks.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/tobias-massow\/\"],\"url\":\"https:\/\/www.digital-chiefs.de\/en\/author\/tobias\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MDR Compliance: Essential Guide for MedTech M&A Deals","description":"MDR Compliance: Future-proof your MedTech acquisitions. Learn due diligence secrets & boost deal value today!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/","og_locale":"en_US","og_type":"article","og_title":"MDR Compliance: Essential Guide for MedTech M&A Deals","og_description":"MDR Compliance: Future-proof your MedTech acquisitions. Learn due diligence secrets & boost deal value today!","og_url":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/","og_site_name":"Digital Chiefs","article_publisher":"https:\/\/www.facebook.com\/digitalchiefs\/","article_published_time":"2026-03-26T08:00:00+00:00","article_modified_time":"2026-06-10T07:47:14+00:00","og_image":[{"width":1880,"height":1253,"url":"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg","type":"image\/jpeg"}],"author":"Tobias Massow","twitter_card":"summary_large_image","twitter_creator":"@digital_chiefs","twitter_site":"@digital_chiefs","twitter_misc":{"Written by":"Tobias Massow","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#article","isPartOf":{"@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/"},"author":{"name":"Tobias Massow","@id":"https:\/\/www.digital-chiefs.de\/en\/#\/schema\/person\/7a9e40318a8c36352e7a694f6df4d5c8"},"headline":"MedTech M&#038;A: Why MDR Compliance Has Become a Deal-Breaker","datePublished":"2026-03-26T08:00:00+00:00","dateModified":"2026-06-10T07:47:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/"},"wordCount":1120,"publisher":{"@id":"https:\/\/www.digital-chiefs.de\/en\/#organization"},"image":{"@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#primaryimage"},"thumbnailUrl":"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg","articleSection":["Smart City & Smart Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/","url":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/","name":"MDR Compliance: Essential Guide for MedTech M&A Deals","isPartOf":{"@id":"https:\/\/www.digital-chiefs.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#primaryimage"},"image":{"@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#primaryimage"},"thumbnailUrl":"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg","datePublished":"2026-03-26T08:00:00+00:00","dateModified":"2026-06-10T07:47:14+00:00","description":"MDR Compliance: Future-proof your MedTech acquisitions. Learn due diligence secrets & boost deal value today!","breadcrumb":{"@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#primaryimage","url":"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg","contentUrl":"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2026\/04\/pexels-4989167.jpg","width":1880,"height":1253},{"@type":"BreadcrumbList","@id":"https:\/\/www.digital-chiefs.de\/en\/medtech-ma-why-mdr-compliance-has-become-a-deal-breaker\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.digital-chiefs.de\/en\/home\/"},{"@type":"ListItem","position":2,"name":"MedTech M&#038;A: Why MDR Compliance Has Become a Deal-Breaker"}]},{"@type":"WebSite","@id":"https:\/\/www.digital-chiefs.de\/en\/#website","url":"https:\/\/www.digital-chiefs.de\/en\/","name":"Digital Chiefs","description":"Architekten des digitalen Deutschlands","publisher":{"@id":"https:\/\/www.digital-chiefs.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.digital-chiefs.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.digital-chiefs.de\/en\/#organization","name":"Digital Chiefs","url":"https:\/\/www.digital-chiefs.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.digital-chiefs.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2020\/05\/cropped-digital-chiefs-logo-klein.jpg","contentUrl":"https:\/\/www.digital-chiefs.de\/wp-content\/uploads\/2020\/05\/cropped-digital-chiefs-logo-klein.jpg","width":190,"height":190,"caption":"Digital Chiefs"},"image":{"@id":"https:\/\/www.digital-chiefs.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/digitalchiefs\/","https:\/\/x.com\/digital_chiefs","https:\/\/www.linkedin.com\/company\/digital-chiefs\/"]},{"@type":"Person","@id":"https:\/\/www.digital-chiefs.de\/en\/#\/schema\/person\/7a9e40318a8c36352e7a694f6df4d5c8","name":"Tobias Massow","description":"Tobias Massow ist Gesch\u00e4ftsf\u00fchrer der Evernine Media GmbH und Herausgeber von Digital Chiefs. Er verantwortet die strategische Ausrichtung des Magazins und des MBF Media Netzwerks.","sameAs":["https:\/\/www.linkedin.com\/in\/tobias-massow\/"],"url":"https:\/\/www.digital-chiefs.de\/en\/author\/tobias\/"}]}},"_links":{"self":[{"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/posts\/14982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/users\/114"}],"replies":[{"embeddable":true,"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/comments?post=14982"}],"version-history":[{"count":7,"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/posts\/14982\/revisions"}],"predecessor-version":[{"id":28782,"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/posts\/14982\/revisions\/28782"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/media\/15529"}],"wp:attachment":[{"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/media?parent=14982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/categories?post=14982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.digital-chiefs.de\/en\/wp-json\/wp\/v2\/tags?post=14982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}